Senesco to Present at the 53rd Annual Meeting of the American Society of Hematology on SNS01-T
December 06 2011 - 9:24AM
Business Wire
Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE
AMEX: SNT) announced today that it will deliver a poster
presentation at the 53rd Annual Meeting of ASH, the American
Society of Hematology. The conference will be held December
10-13th, 2011 at the San Diego Convention Center in San Diego,
California. The Company will present during the Oral and Poster
Abstracts Program that will begin Saturday December 10th, at 5:30
p.m. Pacific Time. The poster presentation, entitled
“Pharmacodynamic, Biodistribution and Toxicology Results for
SNS01-T, a Nanoparticle That Targets eIF5A for the Treatment of
Multiple Myeloma”, will describe the characteristics of SNS01-T,
which is the subject of an on-going clinical study at the Mayo
Clinic. The poster will be presented by Catherine Taylor, Research
Associate from Senesco CSO John Thompson’s research laboratory at
the University of Waterloo in Ontario, Canada. Additional details
about the conference can be found
at: http://www.hematology.org/
About Multiple Myeloma
Multiple myeloma is an incurable cancer of plasma cells, a type
of white blood cell derived from B-lymphocytes, normally
responsible for the production of antibodies. Malignant plasma
cells accumulate in the bone marrow leading to bone lesions and
interfering with the production of normal white blood cells. Median
survival time from first treatment is 2½ to 5 years depending on
disease stage at diagnosis. In the United States there are almost
20,000 newly diagnosed cases of multiple myeloma annually and a
total of approximately 65,000 patients with the disease. Senesco
was previously granted orphan drug status for SNS01-T, the
Company’s lead drug candidate for treatment of multiple
myeloma.
About Senesco Technologies, Inc.
Senesco Technologies is leveraging proprietary technology that
regulates programmed cell death, or apoptosis. Accelerating
apoptosis may have applications in treating cancer, while delaying
apoptosis may have applications treating certain inflammatory and
ischemic diseases. The Company has initiated a clinical study in
multiple myeloma with its lead therapeutic candidate SNS01-T.
Senesco has already partnered with leading-edge companies engaged
in agricultural biotechnology, and is entitled to earn research and
development milestones and royalties if its gene-regulating
platform technology is incorporated into its partners’
products.
Forward-Looking Statements
Certain statements included in this press release are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Actual results could
differ materially from such statements expressed or implied herein
as a result of a variety of factors, including, but not limited to:
the ability of the Company to consummate additional financings; the
development of the Company’s gene technology; the approval of the
Company’s patent applications; the successful implementation of the
Company’s research and development programs and collaborations; the
success of the Company's license agreements; the acceptance by the
market of the Company’s products; the timing and success of the
Company’s preliminary studies, preclinical research and clinical
trials; competition and the timing of projects and trends in future
operating performance, the Company’s ability to comply with the
continued listing standards of the NYSE Amex, as well as other
factors expressed from time to time in the Company’s periodic
filings with the Securities and Exchange Commission (the "SEC"). As
a result, this press release should be read in conjunction with the
Company’s periodic filings with the SEC. The forward-looking
statements contained herein are made only as of the date of this
press release, and the Company undertakes no obligation to publicly
update such forward looking statements to reflect subsequent events
or circumstances.
Senesco (AMEX:SNT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Senesco (AMEX:SNT)
Historical Stock Chart
From Jul 2023 to Jul 2024